Immunome, Inc. (NASDAQ:IMNM) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 15.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 43,865 shares of the company’s stock after selling 8,189 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.07% of Immunome worth $641,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Quest Partners LLC purchased a new stake in Immunome in the second quarter valued at approximately $81,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Immunome in the 2nd quarter valued at $97,000. Arizona State Retirement System boosted its holdings in shares of Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after purchasing an additional 918 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after buying an additional 4,129 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in shares of Immunome during the 3rd quarter worth $219,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Trading Down 1.0 %

Shares of IMNM stock opened at $10.97 on Friday. The firm has a fifty day simple moving average of $12.14 and a 200-day simple moving average of $13.35. The company has a market capitalization of $684.71 million, a PE ratio of -1.35 and a beta of 1.83. Immunome, Inc. has a twelve month low of $8.15 and a twelve month high of $30.96.

Analysts Set New Price Targets

A number of brokerages recently weighed in on IMNM. Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a report on Friday, October 25th. Stephens began coverage on Immunome in a report on Friday, November 8th. They set an “overweight” rating and a $30.00 target price for the company. Finally, Piper Sandler cut their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Immunome presently has a consensus rating of “Buy” and an average target price of $28.83.

Insider Activity

In other Immunome news, CEO Clay B. Siegall purchased 66,057 shares of Immunome stock in a transaction that occurred on Thursday, November 21st. The stock was purchased at an average price of $9.54 per share, with a total value of $630,183.78. Following the completion of the acquisition, the chief executive officer now owns 485,693 shares of the company’s stock, valued at approximately $4,633,511.22. This trade represents a 15.74 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Robert Lechleider purchased 15,805 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was bought at an average price of $9.48 per share, with a total value of $149,831.40. Following the purchase, the insider now owns 15,805 shares of the company’s stock, valued at approximately $149,831.40. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders acquired 102,862 shares of company stock worth $978,045 over the last ninety days. Corporate insiders own 8.60% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.